TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04473508
Drug: Local administration of placebo (saline solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of saline solution in addition with conventional anesthesia for spine surgery
Study: NCT00959959
Drug: TOK-001
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 capsules (325 mg each), once per day
Study: NCT00959959
Drug: TOK-001
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 capsules (325 mg each), once per day
Study: NCT00959959
Drug: TOK-001
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 capsules (325 mg each), once per day
Study: NCT00959959
Drug: TOK-001
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 capsules (325 mg each), once per day
Study: NCT00959959
Drug: TOK-001
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 capsules (325 mg each), once per day with supplement
Study: NCT00959959
Drug: TOK-001
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
Study: NCT00959959
Drug: TOK-001
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 capsules (325 mg each), once per day
Study: NCT00959959
Drug: TOK-001
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
Study: NCT02833415
Drug: [U-13C3] glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of \[U-13C3\] glycerol based on human's body weight such as (50 mg/kg body weight).
Study: NCT02833415
Drug: Placebo (for Empagliflozin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet manufactured to mimic EMPA 10 mg tablet.
Study: NCT00958256
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 intravenously over 3 hours 2 times each day (6 hours total each day) on Days 2, 3, and 4 of every cycle
Study: NCT01769209
Drug: Doxorubicin hydrochloride (HCl)
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously (IV) over 15 min at 60mg/m², on Day 1.
Study: NCT05999994
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT01769209
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intrathecally (IT) at 15 mg, on Day 15.
Study: NCT04386057
Drug: LY3214996
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3214996-daily oral dosage per protocol per 28 day cycle
Study: NCT00004143
Drug: Campath, Chemo and/or TBI Allo SCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.
Study: NCT00049036
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00049036
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00963183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for nebulisation, inhaled. Each subject will receive a single-dose.
Study: NCT02322047
Drug: Placebo (Prazosin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
Study: NCT02322047
Drug: Placebo (Naltrexone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Dosing Days 1-42: 50mg @ 9PM
Study: NCT00413400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
Study: NCT01786655
Drug: NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml. Subjects receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
Study: NCT03905408
Drug: 50 mL of 50% Glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st dose
Study: NCT03905408
Drug: 100 mL of 50% Glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2nd dose
Study: NCT03905408
Drug: 150 mL of 50% Glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3rd dose
Study: NCT03905408
Drug: 200 mL of 50% Glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4th dose
Study: NCT04450446
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy
Study: NCT02006888
Drug: IBI-10090
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02006888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00371826
Drug: Cyclosporine (Calcineurin Inhibitor (CNI))
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00725374
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were to take one tablet of tibolone-matched placebo, per day, every day, for 14 ± 2 days (until the day before surgery).
Study: NCT02616692
Drug: Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-cancer therapy (Sorafenib, an multiple kinase inhibitor), repeated transarterial chemoembolization (TACE) procedures, and hepatic arterial infusion chemotherapy (HAIC)
Study: NCT02104752
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive, matched placebo (Sugar Pill)
Study: NCT01769378
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SQ
Study: NCT04356209
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will take Pravastatin 40 mg per day (From Day 0 to Month 12).
Study: NCT00144690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04676178
Drug: PRA023
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRA023
Study: NCT03665454
Drug: Standard of Care Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25/100 mg tablet(s) of carbidopa/levodopa will be encapsulated and administered according to the subject's home regimen.
Study: NCT00168701
Drug: BG00012
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02505295
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion like intervention group
Study: NCT00436241
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg/m2 po bid on days 1-10 of each 2 week cycle
Study: NCT01358851
Drug: LAS41005
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT03624985
Drug: Placebo Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose
Study: NCT03532841
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet of the same shape,color and taste will be given in the placebo arm
Study: NCT01842100
Drug: Universal antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg twice daily for 7 days starting on the day of induced abortion
Study: NCT01667484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02201849
Drug: Study Drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02201849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03643575
Drug: Vicks Cough Syrup for Chesty Coughs
Normalized name: Vicks Cough Syrup for Chesty Coughs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicks Cough Syrup for Chesty Coughs 15 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
Study: NCT03643575
Drug: Robitussin Extra Strength Chest Congestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robitussin Extra Strength Chest Congestion 5 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
Study: NCT03643575
Drug: Organ-I- NR tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organ-I- NR tablet (containing 200 mg guaifenesin) with 240 mL of water
Study: NCT00041574
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
Study: NCT02324972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01958281
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily
Study: NCT01958281
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg fixed-dose combination (FDC) tablet administered orally once daily
Study: NCT00390312
Drug: Intranasal Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo
Study: NCT00390312
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo
Study: NCT00179465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01000402
Drug: Psychopharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day
Study: NCT03127631
Drug: Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.
Study: NCT03127631
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater \>130mmHg, or other blood pressure lowering medication as applicable.
Study: NCT03517137
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For PET positive (score of 4-5 following Deauville Criteria) patients: Cyclophosphamide is administered as an IV infusion over a period of 30 minutes at 1250 mg/m² on day 2, every 3 weeks (6 cycles)
Study: NCT02631759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl 0,9%) will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~* A phase of 7 days of placebo 250 mg every 12 hours ( morning and evening)~* Then a phase of 7 days of placebo 250 mg every 24 hours (evening).
Study: NCT00153088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00135707
Drug: Dietary Supplement/Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
Study: NCT04481971
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets
Study: NCT04481971
Drug: lactose in capsules gelatin
Normalized name: lactose Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT04299854
Drug: Dinoprostone 10mg
Normalized name: DINOPROSTONE 10MG INSERT,VAG
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal delivery system containing 10mg of dinoprostone placed at the bottom of the vagina
Study: NCT02337933
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcined magnesia capsules of 150 mg, once a day before breakfast
Study: NCT00303745
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00765700
Drug: Topical Ketoprofen 10% Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Administration
Study: NCT00765700
Drug: Topical Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Administration
Study: NCT00032162
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/30/40 mg/qm q4w Dose finding study
Study: NCT01555320
Drug: Qishen Yiqi Dripping Pills
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
Study: NCT01555320
Drug: Qishen Yiqi dripping pills dummy
Normalized name: Caltrate Gummy Bites Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
Study: NCT01829464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 placebo-matching tablets
Study: NCT04137627
Drug: Melatonin 20 MG Oral Capsule
Normalized name: melatonin 20 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration of Melatonin 20 mg in addition to neoadjuvant chemotherapy to observe the antioxidant and onco-static effect.
Study: NCT04137627
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration of placebo capsule in addition to neoadjuvant chemotherapy
Study: NCT02248701
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive placebo (weekly) by intramuscular injection
Study: NCT02248701
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive placebo pill (daily) orally
Study: NCT02053870
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
Study: NCT00963222
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cap placebo/day for 3 month
Study: NCT03870100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: water injection Route of administration: subcutaneous
Study: NCT02207309
Drug: Placebo (for Pazopanib)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04322175
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam Eye Drops
Study: NCT01645306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intravenous injection
Study: NCT00810368
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose placebo tablets x2 daily
Study: NCT02747875
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
Study: NCT01694485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to abrilumab administered by subcutaneous injection
Study: NCT00506909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU BID or 40 IU BID
Study: NCT01495377
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Powder for injection/ infusion fluid solution, 1 mg Infusion TCI 3 ng/ml 60 min ( 0,15 ug/kg/min)
Study: NCT01495377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
Study: NCT03172780
Drug: Diclofenac sodium gel 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
Study: NCT03172780
Drug: Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
Study: NCT03172780
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Gel 4 gm, 4 times a day for 4 weeks
Study: NCT00538291
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00268788
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individually dosed, given twice a week.
Study: NCT01696695
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics
Study: NCT01696695
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line chemotherapy according to effective official Summary of Product Characteristics. The study protocol does not specify any particular therapy.
Study: NCT03570697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo subcutaneous monthly.
Study: NCT03570697
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy~Investigators will up-titrate statin therapy to the maximally tolerated dose, in accordance with local guidelines, prior to randomization.
Study: NCT00766025
Drug: Rosuvastatin Calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single oral dose on days 1, 4, 5, 6, 10-16, 17
Study: NCT04633733
Drug: HL237 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL237 400mg will be administered orally twice a day.
Study: NCT03070366
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: * cisplatin~* 5FU~* carboplatin~* cetuximab
Study: NCT02583542
Drug: AZD2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.
Study: NCT02583542
Drug: AZD6244
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.
Study: NCT03208127
Drug: Treatment with Direct Acting Antiviral tablet
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV Treatment for 12 Weeks
Study: NCT02837146
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction and maintenance phase: Methotrexate 15-20 mg/week from baseline to week 54
Study: NCT02746263
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02040766
Drug: Placebo BAI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was delivered by a single inhalation using a breath-actuated inhaler (BAI) twice each day.
Study: NCT02040766
Drug: Placebo MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was delivered by a single inhalation using a metered-dose inhaler (MDI) twice each day.
Study: NCT04541719
Drug: Patient-controlled remifentanil analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled remifentanil analgesia with a regimen to provide a bolus of 40 μg remifentanil with a lockout interval of 2 min